Patient Versus Physician Perspective in the Management of Chronic Myeloid Leukemia During Treatment with Tyrosine Kinase Inhibitors

被引：0

作者：

Hong Chen

Yan Wen

Yun Zeng

Lie Lin

Bihong Sun

Hongqian Zhu

Huiqing He

Xiaotao Wang

Waiyi Zou

Caifeng Zheng

Liling Zheng

Jinxiong Huang

Liping Pang

Jixian Huang

Yuming Zhang

Haiqing Lin

Zelin Liu

Wanshou Zhu

Qiang Wang

Xuan Zhou

Xiaoli Liu

Hong Qu

Zhenfang Liu

Xin Du

Na Xu

机构：

[1] Nanfang Hospital,Department of Hematology

[2] Southern Medical University,Department of Hematology

[3] Yunnan Hematology Hospital,Department of Hematology

[4] First People’ Hospital of Yunnan,Department of Hematology

[5] Affiliated Hospital of Kunming University of Science and Technology,Department of Hematology

[6] First Affiliated Hospital of Kunming Medical University,Department of Hematology

[7] Hematology Research Center of Yunnan Province,Department of Hematology

[8] Hainan General Hospital,Department of Hematology

[9] People’s Hospital of Guangxi Zhuang Autonomous Region,Department of Hematology

[10] Guizhou Provincial People’s Hospital,Department of Hematology

[11] Zhongshan People’s Hospital,Department of Hematology

[12] Guilin Medical University Affiliated Hospital,Department of Hematology

[13] The First Affiliated Hospital,Department of Hematology

[14] Sun Yat-Sen University,Department of Hematology

[15] Shenzhen Bao An People’s Hospital,Department of Hematology

[16] The Second People’s Hospital of Guangdong Province,Department of Hematology

[17] Liuzhou People’s Hospital,Department of Hematology

[18] Peking University Shenzhen Hospital,Department of Hematology

[19] Yue Bei People’s Hospital,Department of Hematology

[20] Shantou University Medical College,Department of Hematology

[21] Affiliated Hospital of Guangdong Medical University,Department of Hematology and Shenzhen Bone Marrow Transplantation Public Service Platform

[22] Shenzhen People’s Hospital,undefined

[23] Second Clinical Medical College of Jinan University,undefined

[24] First Affiliated Hospital of Southern University of Science and Technology,undefined

[25] Huazhong University of Science and Technology Union Shenzhen Hospital,undefined

[26] Gaozhou People’s Hospital,undefined

[27] Panyu Central Hospital,undefined

[28] The First Affiliated Hospital of Guangxi Medical University,undefined

[29] The First Affiliated Hospital of Shenzhen University,undefined

[30] Shenzhen Second People’s Hospital,undefined

[31] Shenzhen University School of Medicine,undefined

来源：

Oncology and Therapy | 2024年 / 12卷

关键词：

Chronic myeloid leukemia; Patient; Physician; Quality of life; Discrepancies;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：131 / 145

页数：14

共 50 条

[31] The Management of Chronic Myeloid Leukemia in the Era of Second Generation Tyrosine Kinase Inhibitors
Haznedaroglu, Ibrahim C.
Cetiner, Mustafa
Ilhan, Osman
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2011, 21 (02): : 1 - 3
[32] Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia
Rea, Delphine
ANNALS OF HEMATOLOGY, 2015, 94 : S149 - S158
[33] Collaborative cardiovascular management of patients with chronic myeloid leukemia on tyrosine kinase inhibitors
Kondapalli, Lavanya
Worth, Sarah
Hawi, Riem
Vachhani, Pankit
Arora, Garima
Bhatia, Ravi
Lenneman, Carrie G.
VASCULAR MEDICINE, 2020, 25 (03) : 246 - 254
[34] Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia
Delphine Rea
Annals of Hematology, 2015, 94 : 149 - 158
[35] Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia
Quintas-Cardama, Alfonso
Cortes, Jorge E.
Kantarjian, Hagop
CLINICAL LYMPHOMA & MYELOMA, 2008, 8 : S82 - S88
[36] Patient-Versus Physician-Perceptions of Symptoms, Treatment and Management in Chronic Myeloid Leukemia
Chen, Hong
Wen, Yan
Zeng, Yun
Lin, LiE
Du, Xin
Liu, Zhenfang
Sun, Bihong
Zhu, Hongqian
He, Huiqing
Wang, Xiaotao
Zou, Waiyi
Zheng, Caifeng
Zheng, Liling
Huang, Jinxiong
Pang, Liping
Huang, Jixian
Zhang, Yuming
Lin, Haiqing
Liu, Zelin
Zhu, Wanshou
Zhou, Xuan
Wang, Qiang
Liu, Xiaoli
Liu, Qifa
Xu, Na
BLOOD, 2022, 140 : 10841 - 10842
[37] Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors
Gugliotta, Gabriele
Castagnetti, Fausto
Fogli, Miriam
Cavo, Michele
Baccarani, Michele
Rosti, Gianantonio
EXPERT REVIEW OF HEMATOLOGY, 2013, 6 (05) : 563 - 574
[38] Placental transfer of tyrosine kinase inhibitors used for chronic myeloid leukemia treatment
Chelysheva, Ekaterina
Turkina, Anna
Polushkina, Evgenia
Shmakov, Roman
Zeifman, Alexey
Aleshin, Sergey
Shokhin, Igor
Guranda, Dorel
Oksenjuk, Oksana
Mordanov, Sergey
Kazakbaeva, Khamida
Chilov, Ghermes
LEUKEMIA & LYMPHOMA, 2018, 59 (03) : 733 - 738
[39] Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia
Breccia, Massimo
Colafigli, Gioia
Molica, Matteo
Alimena, Giuliana
EXPERT OPINION ON DRUG SAFETY, 2016, 15 (04) : 525 - 533
[40] Phase II trials of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
Ghanem, Hady
Kantarjian, Hagop
Cortes, Jorge
Quintas-Cardama, Alfonso
Jabbour, Elias
EXPERT OPINION ON ORPHAN DRUGS, 2013, 1 (08): : 607 - 623

← 1 2 3 4 5 →